Sign up
Pharma Capital

DaVita, UnitedHealth Group, Walt Disney, Home Depot - PRE-MARKET

A look at the pre-market trade in New York , where the Davita Inc, UnitedHealth Group In c is gaining attention
1512566180_rsz_shutterstock_151335704.jpg
The healthcare sector was in focus before the bell

As futures point lower, several stocks are in focus before the bell.

A notable story is that DaVita Inc (NYSE:DVA), whose shares surged almost 9% to US$66.28 in extended deals after UnitedHealth Group Inc (NYSE:UNH), shares up 0.05% said it will pay just under US$5 billion for DaVita's medical unit.

It will combine it with DaVita's Optum division as it expands into ambulatory care delivery systems.

Meanwhile, also in pre-market news, Home Depot Inc (NYSE:HD) shares lost 2.37% to US$178.45 after hours, having rallied nearly 17% higher in the past three months.

The firm has launched a new US$15bn stock repurchase program and affirmed its 2017 profit and sales outlook as part of an update of the retailer’s strategic priorities.

Wall Street expects American Eagle Outfitters (NYSE:AEO) to report quarterly earnings at US$0.38 per share on revenues of US$960.97 million before the opening bell.

AEO will report after the  bell. Shares added 2.43% to US$16.50 in pre-market deals.

Walt Disney Co (NYSE:DIS) shares shed 0.58% tom US$106.60 in pre-market.

The group is said to be nearing a deal to buy most of Rupert Murdoch’s 21st Century Fox (NASDAQ:FOXA) with an announcement expected as soon as next week.

Disney is reportedly in advanced talks with Fox to buy its film studio, cable channels, a stake in the Hulu streaming service and international assets, including the Star cable and media company in India and British broadcaster Sky plc (LON:SKY).

Giles_55af4ddca6481.jpg


Register here to be notified of future DVA Company articles
View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.